Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

N818: A specialized IBD unit infusion center is preferred by patientsECCO '17 Barcelona
Year: 2017
Authors:

Koslowsky B., Mazuz B., Goldin E., Bar-Gil Shitrit A.

Shaare Zedek Medical Center, Gastroenterology, Jerusalem, Israel

N819: Analysis of the role of nursing in a IBD unitECCO '17 Barcelona
Year: 2017
Authors:

Ruiz N., Camargo R., Alcain G., Carreño R., Recio D.

Hospital Virgen de La Victoria, Department of Gastroenterology, Malaga, Spain

N820: The value and perception of IBD patients on electronic news letter as a mode of patient-medical team communicationECCO '17 Barcelona
Year: 2017
Authors:

Haj Natour O., Orbach-Zingboim N., Ungar B., Skenizes D., Kopylov U., Eliakim R., Ben-Horin S.

Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel

N821: Communication with IBD nurse is associated with disease severity but not with better adherence to treatmentECCO '17 Barcelona
Year: 2017
Authors:

Abraham C.*1, Ruhimovich N.1, Benjaminov F.2, Konikoff F.M.3,4, Naftali T.3

1Meir Medical Center, Department of Gastroenterology & Hepatology, Kfar Saba, Israel 2Tel Aviv university Sackler school of medicin, internal medicine, Tel aviv, Israel 3Meir medical center, Gastroenterology, Kfar Saba, Israel 4Tel Aviv university Sackler school of medicin, internal medicine, Tel Aviv, Israel

N822: Non-programmed assistance of IBD patients in our institution. Ratios of activity and effectiveness of IBD-nurse roleECCO '17 Barcelona
Year: 2017
Authors:

Cano Sanz N., Sierra M., Suarez P., Gundín M.J.F.

Hospital Universitario de Leόn - CAULE, Gastroenterology - IBD unit, Leόn, Spain

N823: The linked project, creating networkECCO '17 Barcelona
Year: 2017
Authors:

Navarro Correal E.*1, Marin Sanchez L.2

1Vall d'Hebron university Hospital, Gastroenterolgy, Barcelona, Spain 2Hospital Universitari Germans Trias I Pujol, Department of Gastroenterology & Hepatology and CIBEREHD, Badalona, Spain

N824: Impact of educational intervention on inflammatory bowel disease nurse specialistECCO '17 Barcelona
Year: 2017
Authors:

Barros J., Renosto F., Silva R., Baima J., Farineli E., Biondi R., Dorna M., Saad-Hossne R., Sassaki L.

Paulista State University - Botucatu Medical School, Botucatu, Brazil

NO001: Clinical and psychological factors associated with Erectile Dysfunction in inflammatory bowel disease patientsECCO '17 Barcelona
Year: 2017
Authors:

Barros J., Baima J., Renosto F., Sibia C., Silva R., Farineli E., Andriolli G., Dorna M., Saad-Hossne R., Sassaki L.

Paulista State University - Botucatu Medical School, Botucatu, Brazil

NO002: Decision-making about emergency and planned stoma surgery for IBD: a qualitative exploration of patient and clinician perspectivesECCO '17 Barcelona
Year: 2017
Authors:

Dibley L.*1, Czuber-Dochan W.1, Duncan J.2, Artom M.1, Burch J.3, Wade T.1, Verjee A.4, Cann D.4, Warusavitarne J.3, Norton C.1

1King's College London, Florence Nightingale Faculty of Nursing & Midwifery, London, United Kingdom 2Guy's & St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom 3St Mark's Hospital, Harrow, Gastroenterology, London, United Kingdom 4Patient & Public Involvement Team, London, United Kingdom

NO003: IBD nurses as integral part of a multidisciplinary IBD team: prospective study on view on patient outcomesECCO '17 Barcelona
Year: 2017
Authors:

Coenen S.*1, Weyts E.1, Geens P.1, Vermeire S.1, Ferrante M.1, Noman M.1, Ballet V.1, Vanhaecht K.2, Van Assche G.1

1UZ Leuven, Gastroenterology, Leuven, Belgium 2UZ Leuven, Quality, Leuven, Belgium

OP001: Whole genome sequencing and imputation in inflammatory bowel disease identifies 26 novel loci and offers therapeutically-relevant mechanistic insightsECCO '17 Barcelona
Year: 2017
Authors:

Moutsianas L.*1, De Lange K.1, Luo Y.1,2,3, Lee J.4, Jostins L.5, Lamb C.6, Kennedy N.7, Mansfield J.8, Parkes M.4, Barrett J.1, Anderson C.1 UK Inflammatory Bowel Disease Genetics Consortium, Various, United Kingdom

1Wellcome Trust Sanger Institute, Human Genetics, Hinxton, Cambridge, United Kingdom 2Broad Institute of Harvard and MIT, Program in Medical and Population Genetics, Cambridge, United States 3Harvard Medical School, Division of Genetics and Rheumatology, Boston, United States 4Addenbrooke's Hospital, Inflammatory Bowel Disease Research Group, Cambridge, United Kingdom 5Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom 6Newcastle University, Newcastle upon Tyne, United Kingdom 7University of Exeter, Precision Medicine Exeter, Exeter, United Kingdom 8University of Newcastle, Human Genetics, Newcastle upon Tyne, United Kingdom

OP002: Epigenetic biomarkers to detect ulcerative colitis-associated neoplasia: results from phase I of the ENDCAP-C studyECCO '17 Barcelona
Year: 2017
Authors:

Iqbal T.*1, Beggs A.1, Taniere P.2, Wallis Y.3, Mehta S.4, Magill L.4, Deeks J.4, Matthews G.1, Morton D.1 EndCAP-C Consortium

1University of Birmingham, Institute of Cancer & Genomic Sciences, Birmingham, United Kingdom 2University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom 3West Midlands Regional Genetics Centre, Birmingham, United Kingdom 4University of Birmingham, Birmingham Clinical Trials Unit, Birmingham, United Kingdom

OP003: Increased risk of acute arterial events in young patients with severely active inflammatory bowel disease: a nationwide French cohort studyECCO '17 Barcelona
Year: 2017
Authors:

Kirchgesner J.*1,2, Beaugerie L.1, Carrat F.3,4, Nyboe Andersen N.5, Jess T.5,6, Schwarzinger M.7,8 For the BERENICE Study Group

1Saint-Antoine Hospital, AP-HP, Gastroenterology, Paris, France 2INSERM, University Paris 06, UMR S 1136, Paris, France 3Hopital Saint Antoine, Department of Public Health, Paris, France 4INSERM, University Paris 06, UMR S 1136, Paris, France 5Statens Serum Institute, Department of Epidemiology Research, Copenhagen, Denmark 6Frederiksberg Hospital, Institute of Preventive Medicine, Frederiksberg, Denmark 7INSERM, UMR 1137, Paris, France 8THEN, Translational Health Economics Network, Paris, France

OP004: Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Le Bourhis L.1, Corraliza A.2, Auzolle C.1, Ricart E.2, Hawkey C.3, Lindsay J.O.4, Clark M.3, Rogler G.5, Satsangui J.6, Haller D.7, Panes J.2, Salas A.2, Allez M.*1

1Hôpital Saint-Louis INSERM, U1160 – Intestinal Immunity in Inflammation and Cancer, Paris, France 2IDIBAPS, Hospital Clínic, Gastroenterology, Barcelona, Spain, Barcelona, Spain 3University of Nottingham, Gastroenterology, Nottingham, United Kingdom 4Barts and The London, Queen Mary University of London, Centre for Immunology, The Blizard Institute, London, United Kingdom 5University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Swaziland 6Western General Hospital, Gastrointestinal Unit, Centre for Genomic and Experimental Medicine, Edinburgh, United Kingdom 7Technical University Munich, Department of Nutrition and Immunology, Freising, Germany

OP005: The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the efficacy and safety across ItalyECCO '17 Barcelona
Year: 2017
Authors:

Guidi L.1, Fiorino G.*2, Variola A.3, Manetti N.4, Fries W.5, Rizzuto G.6, Bossa F.7, Cappello M.8, Biancone L.9, D'Incà R.10, Cantoro L.11, Castiglione F.12, Principi M.13, Annunziata M.L.14, Di Girolamo M.15, Terpin M.M.16, Cortelezzi C.C.17, Costa F.18, Amato A.19, Di Sabatino A.20, Saibeni S.21, Meucci G.22, Petruzzellis C.23, Tari R.24, Gugliemi F.W.25, Armuzzi A.26, Danese S.2, Geccherle A.3, Rogai F.4, Ventra A.5, Orlando A.6, Andriulli A.7, Scrivo B.8, Troncone E.9, Caccaro R.10, Kohn A.11, Nardone O.12, Annese V.27

1Complesso Integrato Columbus, Fondazione Policlinico Gemelli Universita' Cattolica, Internal Medicine and Gastroenterology, Rome, Italy 2Humanitas Research Hospital and University, Gastroenterology and IBD Center, Rozzano, Italy 3Sacro Cuore Don Calabria Hospital, Gastroenterology and Hepatology, Negrar, Italy 4AOU Careggi, DEA, Gastroenterology, Florence, Italy 5University of Messina, Clinical Unit for Chronic Bowel Disorders, Messina, Italy 6Riuniti Villa Sofia - Cervello Hospital, Internal Medicine 2, Palermo, Italy 7IRCCS-CSS Hospital, Gastroenterology, San Giovanni Rotondo, Italy 8University Hospital, Gastroenterology, Palermo, Italy 9Tor Vergata, Gastroenterology, Roma, Italy 10University of Padova, Gastroenterology, Padova, Italy 11S. Camillo-Forlanini Hospital, Gastroenterology, Rome, Italy 12Federico II University, Gastroenterology, Naples, Italy 13University Bari, Gastroenterology, Bari, Italy 14IRCCS Policlinico, Gastroenterology & Digestive Endoscopy Unit, San Donato, Milano, Italy 15University Hospital, Gastroenterology, Modena, Italy 16AO Hospital, Gastroenterology and Endoscopy, Legnano, Italy 17AOU di Circolo Fondazione Macchi, Gastroenterology, Varese, Italy 18AOUP, Gastroenterology, Pisa, Italy 19Ospedale Valduce, Gastroenterology, Como, Italy 20S.Matteo Hospital Foundation, University of Pavia, First Department of Medicine, Pavia, Italy 21ASST Rhodense, Gastroenterology Unit, Rho, Italy 22S. Giuseppe Hospital, Gastroenterology, Milano, Italy 23Poliambulanza Hospital, Gastroenterology and Digestive Endoscopy, Brescia, Italy 24AOU Maggiore, Gastroenterology, Novara, Italy 25S. Pellegrino Hospital, Gastroenterology, Trani, Italy 26Complesso Integrato Columbus - Catholic University, Internal Medicine and Gastroenterology, Rome, Italy 27Valiant Clinic, Gastroenterology, Dubai, United Arab Emirates

OP006: Correlation of durability of response, serum trough concentrations and outcome parameters: long-term follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) trialECCO '17 Barcelona
Year: 2017
Authors:

Pouillon L.*1, Ferrante M.1, Van Assche G.1, Rutgeerts P.1, Noman M.1, Vande Casteele N.2, Gils A.3, Vermeire S.1

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium 2University of California San Diego, Department of Medicine, La Jolla, CA, United States 3University of Leuven, Department of Pharmaceutical Sciences, Leuven, Belgium

OP007: A multi-centre double blind randomised placebo-controlled study of the use of rectal tacrolimus in the treatment of resistant ulcerative proctitisECCO '17 Barcelona
Year: 2017
Authors:

Lawrance I.C.*1,2, Baird A.1, Lightowler D.2, Radford-Smith G.3, Andrews J.M.4, Connor S.5

1University of Western Australia, Medicine and Pharmacology, Perth, Australia 2Saint John of God Hospital, Centre for Inflammatory Bowel Diseases, Subiaco, Australia 3University of Queensland School of Medicine, IBD Research Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia 4University of Adelaide, School of Medicine, Adelaide, Australia 5University of NSW, Medicine, South Western Sydney Clinical School, Sydney, Australia

OP008: An innovative treatment for refractory perianal fistulas in Crohn's disease: local micro reinjection of autologous fat and adipose derived stromal vascular fractionECCO '17 Barcelona
Year: 2017
Authors:

Serrero M.*1, Philandrianos C.2, Visee C.3, Veran J.2, Orsoni P.3, Sabatier F.2, Grimaud J.-C.1

1Hopital Nord, Gastroenterology, Marseille, France 2Aix-Marseille, Marseille, France 3Hopital Nord, Visceral Surgery, Marseille, France

OP009: Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn's disease: 52-week results of a phase III randomised controlled trialECCO '17 Barcelona
Year: 2017
Authors:

Panes J.*1, García-Olmo D.2, Van Assche G.3, Colombel J.-F.4, Reinisch W.5, Baumgart D.C.6, Nachury M.7, Ferrante M.3, Kazemi-Shirazi L.5, Grimaud J.C.8, de la Portilla F.9, Goldin E.10, Richard M.P.11, Diez M.C.11, Danese S.12

1Hospital Clínic de Barcelona, Dept of Gastroenterology, Barcelona, Spain 2Hospital U. Fundaciόn Jiménez-Díaz, Madrid, Spain 3University Hospitals Leuven, KU Leuven, Leuven, Belgium 4Icahn School of Medicine at Mount Sinai, New York, United States 5Medical University of Vienna, Vienna, Austria 6Charité Medical School - Humboldt-University of Berlin, Berlin, Germany 7CHU Lille, Lille, France 8Hôpital Nord, Marseille, France 9Hospital Virgen del Rocío, Sevilla, Spain 10Sharee Zedek MC, Jerusalem, Israel 11TiGenix, Madrid, Spain 12Istituto Clinico Humanitas, Milano, Italy

OP010: Long term efficacy and safety of Ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through 2 yearsECCO '17 Barcelona
Year: 2017
Authors:

Sandborn W.1, Rutgeerts P.2, Gasink C.3, Jacobstein D.3, Gao L.-L.3, Johanns J.3, Sands B.4, Hanauer S.B.5, Targan S.6, Ghosh S.7, de Villiers W.J.S8, Colombel J.-F.4, Feagan B.G.*9

1University of California San Diego, La Jolla, United States 2University Hospital, Gasthuisberg, Leuven, Belgium 3Janssen Research & Development, LLC, Spring House, United States 4Icahn School of Medicine at Mt Sinai, New York, United States 5Northwestern University Feinberg School of Medicine, Chicago, United States 6Cedars-Sinai Medical Center, Los Angeles, United States 7University of Birmingham, Birmingham, United Kingdom 8University of Stellenbosch, Stellenbosch, South Africa 9Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ont., Canada